Tag Archives: pandemics

Can Traditional Medicine Cure COVID-19? China’s Take

Around the world officials are advising people to be wary of alternative treatments for covid-19. The opposite is true in China, where remedies known as traditional Chinese medicine (TCM) are being heavily promoted by the state. In January 2020, as the crisis escalated, the health ministry listed TCM treatments among those it recommended for the disease. It sent nearly 5,000 specialists to Hubei to administer them to patients (including sufferers at a sports centre in Wuhan that was turned into a TCM hospital for people with mild symptoms). Now China is keen to promote its remedies abroad.  TCM practitioners have joined Chinese medical teams sent to help manage outbreaks in Cambodia, Iraq and Italy. In mid-March, 2020 state media quoted a Tanzanian health official saying that China’s use of TCM for covid-19 may be “a model” for Africa to follow…

The use of animals in TCM sometimes involves appalling cruelty. One of the TCM remedies that the health ministry has recommended for use in the treatment of covid-19 patients includes powdered bear bile. In China this is often extracted from live bears kept in grim farms even though its active ingredient can be created synthetically. In February 2020 China banned the sale of wild animals as food—close contact in markets between live specimens and merchants may have helped the coronavirus to leap from animal to human. But the new rules do not prevent trappers and breeders from selling animal parts for use in TCM.

Officials do not say that traditional remedies can cure covid-19. But they do claim that TCM can reduce death rates by preventing patients with mild or moderate symptoms from developing more serious ones. They also say that TCM can speed up recovery. A website set up by China Daily, a state newspaper, called “Fighting covid-19 the Chinese way”, says that TCM can “remove the trash which causes illness”, leaving the virus “no room to survive”.

Excerpts from Fighting it the Chinese Way: Traditional Medicine, Economist, Apr. 11, 2020

U.S. Desperation for Face Masks: Wild West or Piracy?

From Europe to South America, U.S. allies are complaining about the superpower’s “Wild West” tactics in outbidding or blocking shipments to buyers who have already signed deals for vital medical supplies. …”Money is irrelevant. They pay any price because they are desperate,” one high-level official in German Chancellor Angela Merkel’s ruling CDU/CSU group told Reuters….In April 5, 2020, US President Trump said he was signing a directive to stop the export of N95 respirator masks, which provide essential protection for health-care workers, and other U.S. medical equipment. Furthermore, 3M, a US company, said that the White House had ordered it to stop all shipments to Canada and Latin America of respirators that it manufactures in the U.S., despite what 3M called “significant humanitarian implications.”

In another case, an order of 200,000 masks bound for Germany was diverted to the U.S….Germany’s Secretary of Interior Andreas Geisel called it an “act of modern piracy.” He stated that: “even in times of global crisis, you shouldn’t use Wild West methods.”

U.S. allies complain of ‘Wild West’ tactics in race for medical supplies, Reuters, April 56, 2020

Can’t Treat Covid-19 with Flip-Flops

The U.S. Covid-19 response remains a work in progress—fragmented, chaotic, and plagued by contradictory messaging from political leaders, [such as the flip-flops on the use of face masks, see Stop Buying Face Masks , Learn How to Make Your Own Face Mask]. …

 “We don’t have a national plan,” says epidemiologist Michael Osterholm of the University of Minnesota, Twin Cities. “We are going from press conference to press conference and crisis to crisis … trying to understand our response.”…Even if lockdowns succeed at halting the virus…. the United States needs to marshal massive resources to monitor for new outbreaks and quickly contain them…. Identifying cases and contacts and isolating them will require a huge increase in public health workers at the local level….The absence of nationwide coordination highlights the division of legal power between the federal and state governments…. Governors, not federal officials, typically hold police powers to shut businesses and enforce curfews. But many are reluctant to invoke those powers and suffer the political costs without clear direction from above….“The closest comparison here, in terms of national mobilization, is a war. And there is no way the United States would fight a war as 50 separate states.”

Excerpts from United States Strains to Act as Cases Set Record, Science Magazine, Apr. 3, 2020, at 6488.

Pandemic Counter-Measures: DARPA

The US military supports US Government responses to public health emergencies such as Ebola, which can cause regional destabilization and spread through global travel. Warfighters must also operate in regions where diseases like chikungunya and dengue are endemic, and even seemingly mild challenges like seasonal influenza affect force readiness. In addition to these naturally occurring threats, terrorists and other potential adversaries have a growing palette of biological tools to engineer new biological threats. Existing capabilities to respond to an outbreak and develop therapeutics often take years or even decades to achieve results. Recent examples of public health emergencies have demonstrated a national and global inability to develop effective preventive or therapeutic solutions in a relevant timescale when an infectious threat emerges. The threat of infectious agents on US and global national security can be mitigated if the DoD has the capability to rapidly deploy and impart near-immediate immunity to military personnel and civilian populations for known and newly emerging pathogens.

The goal of P3 is to achieve an integrated capability that can deliver pandemic prevention countermeasures to patients within 60 days of an outbreak. P3 aims to revolutionize outbreak response by enabling rapid discovery, characterization, production, and testing of efficacious medical countermeasures. P3 will innovate in the following areas: (1) Generation of virus stock (including viral unknowns); (2) Rapid evolution of antibody candidates; and (3) Gene-encoded antibody delivery methods.

Excerpts from  The Biological Technologies Office (BTO) of the Defense Advanced Research Projects Agency (DARPA) Proposers Day March 2, 2017 

The Next Pandemic and the US Military

U.S. military forces are the front line of U.S. national security, but as a globally deployed force they are also on the front line of any new pathogen-based health threat that may emerge [including also due to biological warfare]. As overall human activity pushes ever further into previously undeveloped territory, the likelihood of exposure to new pandemic diseases increases.  The 2009 Army Posture Statement, cites a World Health Organization estimate of between 20 and 50 percent of the world’s population being affected if a pandemic were to emerge. WHO forecasts “it may be six to nine months before a vaccine for a pandemic virus strain becomes available.” In a separate report on pandemic influenza, the WHO describes several challenges to producing sufficient volumes of vaccine using current, egg-based protein-production technology, including the likelihood that two doses per person could be required due to the absence of pre-existing immunity.

In short, the potential for a pandemic exists and current technological limitations on defensive measures put the health and readiness of U.S. military forces at risk. A technological solution to increase the speed and adaptability of vaccine production is urgently needed to match the broad biological threat.

DARPA’s Blue Angel program seeks to demonstrate a flexible and agile capability for the Department of Defense to rapidly react to and neutralize any natural or intentional pandemic disease. Building on a previous DARPA program, Accelerated Manufacture of Pharmaceuticals, Blue Angel targets new ways of producing large amounts of high-quality, vaccine-grade protein in less than three months in response to emerging and novel biological threats. One of the research avenues explores plant-made proteins for candidate vaccine production.“Vaccinating susceptible populations during the initial stage of a pandemic is critical to containment,” said Dr. Alan Magill, DARPA program manager. “We’re looking at plant-based solutions to vaccine production as a more rapid and efficient alternative to the standard egg-based technologies, and the research is very promising.”

In a recent milestone development under Blue Angel, researchers at Medicago Inc. produced more than 10 million doses (as defined in an animal model) of an H1N1 influenza vaccine candidate based on virus-like particles (VLP) in one month….“The results we’ve achieved here with plant-based production of vaccines represent both significant increase in scale and decrease in time-to-production over previous production capabilities in the same time period. The plant-made community is now better positioned to continue development and target FDA approval of candidate vaccines,” Magill said. “Once the FDA has approved a plant-made vaccine candidate, the shorter production times of plant-made pharmaceuticals should allow DoD to be much better prepared to face whatever pandemic next emerges.”

DARPA Makes 10 Million Strides in the Race to Contain a Hypothetical Pandemic, July 25, 2012